2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $5.7B | $6.2B | $5.9B | $7B | $7.9B |
Cost of Revenue | $3.9B | $4.4B | $4.4B | $5.1B | $5.6B |
Gross Profit | $1.8B | $1.8B | $1.5B | $1.9B | $2.3B |
Gross Profit % | 31% | 29% | 25% | 27% | 29% |
R&D Expenses | $29M | $22M | $19M | $23M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $29M | $207M | $743M | $313M | $367M |
Dep. & Amort. | $370M | $420M | $380M | $407M | $477M |
Def. Tax | -$44M | $59M | -$9.7M | -$23M | $0 |
Stock Comp. | $43M | $49M | $66M | $77M | $84M |
Chg. in WC | -$11M | -$116M | -$57M | -$62M | $13M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $1.2B | $817M | $587M | $93M | $787M |
ST Investments | $6.8M | $0 | $95M | $11M | $0 |
Cash & ST Inv. | $1.2B | $817M | $681M | $104M | $787M |
Receivables | $442M | $373M | $544M | $512M | $583M |
Inventory | $599M | $595M | $549M | $790M | $754M |
Fiscal Q1 2025 started strong with $2 billion in consolidated net sales and adjusted EBITDA growth in key segments like Foodservice (+10%) and PCB Pet and Grocery, driven by cost management and operational efficiencies.
The company raised the bottom end of its FY 2025 adjusted EBITDA guidance by $10 million to a range of $1.42 billion to $1.46 billion, reflecting strong Q1 performance but maintaining caution due to risks like avian influenza and macroeconomic uncertainties.
Avian influenza is expected to create a $30 million to $50 million headwind in fiscal Q2, but management is confident in recovering these impacts over the balance of the fiscal year, assuming no further outbreaks and successful supply recovery.
Pet segment volumes declined 13% due to SKU rationalization, pricing elasticity, and customer inventory adjustments, but profitability improved. Innovation efforts, including the relaunch of Nutrish and new product launches, are expected to drive growth in late FY 2025 and into FY 2026.
The company repurchased 2.6 million shares since the fiscal year began, maintaining leverage neutrality at 4.3x, and continues to evaluate M&A opportunities with a focus on valuation and strategic fit.